Detalles de la búsqueda
1.
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
Lancet;
402(10405): 871-881, 2023 09 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37478883
2.
NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model.
Cancer Immunol Immunother;
72(9): 3003-3012, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37289257
3.
Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer.
Acta Oncol;
61(4): 403-408, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34913815
4.
Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer.
J Nanobiotechnology;
20(1): 417, 2022 Sep 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-36123677
5.
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
Lancet Oncol;
22(10): 1448-1457, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34529930
6.
Financial relationships between industry and principal investigators of US cooperative group randomized cancer clinical trials.
Int J Cancer;
149(9): 1683-1690, 2021 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34173669
7.
Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma.
Gynecol Oncol;
161(3): 645-652, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33795130
8.
A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model.
J Nanobiotechnology;
19(1): 416, 2021 Dec 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34895262
9.
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC.
Lancet Oncol;
23(4): e156, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35358456
10.
Optimizing Radiotherapy with Immunotherapeutic Approaches.
Adv Exp Med Biol;
995: 53-71, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28321812
11.
Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.
Mol Ther;
22(8): 1494-1503, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24791940
12.
Progress in the management of limited-stage small cell lung cancer.
Cancer;
120(6): 790-8, 2014 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24327434
13.
Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer.
Ann Surg Oncol;
21(1): 306-14, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24197760
14.
Hybridizing mechanistic mathematical modeling with deep learning methods to predict individual cancer patient survival after immune checkpoint inhibitor therapy.
Res Sq;
2024 Mar 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38586046
15.
Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy.
J Exp Clin Cancer Res;
43(1): 70, 2024 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38443968
16.
Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma.
Radiother Oncol;
193: 110121, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38311031
17.
Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer.
Cancer;
119(18): 3402-10, 2013 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23798353
18.
Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.
Cancer;
119(10): 1768-75, 2013 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23423860
19.
The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma.
Ann Surg;
258(3): 500-7, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24022442
20.
Metformin use and improved response to therapy in esophageal adenocarcinoma.
Acta Oncol;
52(5): 1002-9, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22950385